Department of Surgery and Medical-Surgical Specialties, Medicine and Dentistry School, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, 15706, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Methodology and Statistics Unit, Galicia Sur Health Research Institute (IISGS), 36312, Vigo, Spain.
Oral Oncol. 2019 Dec;99:104465. doi: 10.1016/j.oraloncology.2019.104465. Epub 2019 Nov 20.
Oral squamous cell carcinoma (OSCC) is often diagnosed at advanced stages and is associated with poor survival rates. Increasing evidence suggests that microRNAs (miRNAs) present in liquid biopsies could be potential biomarkers for non-invasive OSCC diagnosis. Here, we performed a comprehensive meta-analysis to evaluate the overall diagnostic accuracy of blood and salivary miRNAs in detecting OSCC. A literature search using PubMed EMBASE, Web of Science, LILACS, Scopus, and the Cochrane Library was undertaken up to February 2019. Study quality was assessed with the Quality Assessment for Studies of Diagnostic Accuracy-2, and sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and their corresponding 95% confidence intervals (CIs) were calculated using a bivariate random-effect meta-analysis model. Meta-regression and subgroup analyses were performed to assess the heterogeneity. Twenty-five study units from 16 articles with 2562 subjects were included in this meta-analysis. The pooled sensitivity and specificity of blood and salivary miRNAs in the diagnosis of OSCC were 0.78 (95% CI: 0.76-0.80) and 0.82 (95% CI: 0.79-0.84), respectively, and the pooled positive and negative likelihood ratios were 4.31 (95% CI: 3.38-5.51) and 0.25 (95% CI: 0.20-0.32), respectively. The overall area under the curve was 0.91 (95% CI: 0.88-0.93), with a diagnostic odds ratio of 21.46 (95% CI: 13.37-34.45). These findings provide evidence regarding the potential clinical application of blood and salivary miRNAs as a novel, non-invasive, and accurate diagnostic tool for OSCC.
口腔鳞状细胞癌 (OSCC) 通常在晚期诊断，生存率较差。越来越多的证据表明，液体活检中的 microRNAs (miRNAs) 可能是用于非侵入性 OSCC 诊断的潜在生物标志物。在这里，我们进行了一项综合荟萃分析，以评估血液和唾液 miRNAs 检测 OSCC 的总体诊断准确性。使用 PubMed、EMBASE、Web of Science、LILACS、Scopus 和 Cochrane 图书馆进行文献检索，检索时间截至 2019 年 2 月。使用诊断准确性研究的质量评估-2 评估研究质量，并使用双变量随机效应荟萃分析模型计算敏感性、特异性、阳性似然比、阴性似然比、诊断比值比及其相应的 95%置信区间 (CI)。进行荟萃回归和亚组分析以评估异质性。本荟萃分析共纳入了 16 篇文章中的 25 项研究，共 2562 名受试者。血液和唾液 miRNAs 诊断 OSCC 的汇总敏感性和特异性分别为 0.78 (95% CI: 0.76-0.80) 和 0.82 (95% CI: 0.79-0.84)，汇总阳性和阴性似然比分别为 4.31 (95% CI: 3.38-5.51) 和 0.25 (95% CI: 0.20-0.32)。总体曲线下面积为 0.91 (95% CI: 0.88-0.93)，诊断比值比为 21.46 (95% CI: 13.37-34.45)。这些发现为血液和唾液 miRNAs 作为 OSCC 新型非侵入性准确诊断工具的潜在临床应用提供了证据。
